Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 12-month double-blind, double-dummy, randomized, parallel group, multicenter efficacy and safety study of Symbicort pMDI 2 x 160/4.5 microg bid and 2 x 80/4.5 microg bid compared to formoterol Turbuhaler 2 x 4.5 microg bid and placebo in patients with COPD

X
Trial Profile

A 12-month double-blind, double-dummy, randomized, parallel group, multicenter efficacy and safety study of Symbicort pMDI 2 x 160/4.5 microg bid and 2 x 80/4.5 microg bid compared to formoterol Turbuhaler 2 x 4.5 microg bid and placebo in patients with COPD

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 03 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Budesonide/formoterol (Primary) ; Formoterol
  • Indications Chronic obstructive pulmonary disease
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms SUN
  • Sponsors AstraZeneca
  • Most Recent Events

    • 18 May 2011 Results relating to gene polymorphisms presented at the 107th International Conference of the American Thoracic Society.
    • 03 Nov 2010 Bone mineral density results in a subgroup of patients with moderate to very severe disease have been presented at the 76th Annual Meeting of the American College of Chest Physicians: Chest 2010.
    • 20 May 2009 COPD exacerbation results reported at the 105th International Conference of the American Thoracic Society.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top